Ketorolac IM Dosing Frequency for an 18-Year-Old Female
For an 18-year-old female, ketorolac 10 mg IM should not be given—the correct IM dose is 60 mg every 6 hours (not 10 mg), with a maximum daily dose of 120 mg and treatment duration not exceeding 5 days. 1
Correct Dosing Parameters
The FDA-approved dosing for ketorolac IM in patients under 65 years of age is:
- Single-dose regimen: 60 mg IM as one-time administration 1
- Multiple-dose regimen: 30 mg IM every 6 hours, with maximum daily dose of 120 mg 1
- Maximum treatment duration: 5 days total (combined parenteral and oral therapy) 1
The 10 mg dose you mentioned does not align with standard IM dosing protocols. The 10 mg formulation is typically reserved for oral administration after transitioning from parenteral therapy. 2
Dosing Frequency Specifics
For multiple-dose treatment in a healthy 18-year-old female:
- Administer 30 mg IM every 6 hours (not more frequently) 1
- This allows for a maximum of 4 doses per 24-hour period (120 mg total daily) 1
- The analgesic effect begins in approximately 30 minutes with maximum effect at 1-2 hours and duration of 4-6 hours 1
Critical Safety Considerations
Duration limitation is non-negotiable: Ketorolac therapy must not exceed 5 days due to increased risk of serious adverse events including gastrointestinal bleeding, perforation, and renal impairment with prolonged use. 1, 3
Contraindications to verify before administration:
- History of aspirin/NSAID-induced asthma 2, 4
- Active or history of peptic ulcer disease or GI bleeding 4, 5
- Cerebrovascular hemorrhage 2, 4
- Concurrent anticoagulant use 4, 5
- Pregnancy (ketorolac is contraindicated) 2, 1
Baseline monitoring recommended:
Common Pitfalls to Avoid
Do not increase dose or frequency for breakthrough pain—instead, consider supplementing with low-dose opioids if not contraindicated. 1
Do not mix ketorolac in a syringe with morphine, meperidine, promethazine, or hydroxyzine, as this causes precipitation. 1
Do not use concurrent NSAIDs or SSRIs/SNRIs due to increased risk of adverse events and bleeding. 5
The incidence of serious adverse events, particularly GI bleeding and renal impairment, increases significantly with high doses and prolonged therapy beyond 5 days, especially in vulnerable populations. 3 While your patient is young and presumably healthy, strict adherence to dosing limits and duration restrictions is essential to minimize these risks. 3, 6